Sign in
Taking people in ItalyPhase 1/2

Tests niraparib with abemaciclib in people with late-stage ovarian cancer

Tests two cancer drugs together in adults with ovarian cancer after other treatments.

Key facts

Who runs it
Fondazione IRCCS Istituto Nazionale Dei Tumori
Where
Milan, ItalySee the site
Registry title
A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)
Status
Recruiting
Phase
Phase 1/2
People taking part
73 people, planned
Started
18 Sept 2024
Expected to end
28 Sept 2029
Type of study
Interventional
Record updated
25 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult women with ovarian cancer who need a later-line treatment. It tests niraparib together with abemaciclib.

Age
18 years or older
Sex
Women only

Where in Italy

  • Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Tests niraparib with abemaciclib in people with late-stage ovarian cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
25 June 2026